Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
iPSCs are Transforming Drug Discovery, Toxicity Testing, Disease Modeling, and Beyond
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using adult cells. They are derived from somatic cells by reprogramming artificially and turning on the expression of specific pluripotency genes. The reprogramming is achieved using different techniques with varying efficiencies. The iPSC technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He and his team introduced four specific genes encoding transcription factors and converted adult cells into pluripotent stem cells. [Read more…]
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
SINGAPORE — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). [Read more…]
When a Network Matters! Functional iPSC-derived Endothelial Cells Finally Arrive
Authored By: Aristotle Kayafas, Trailhead Biosystems Inc.
60,000 miles of blood vessels run all throughout the average human body (Cleveland Clinic, 2022). Mostly tiny arteries and veins, they carry life-giving blood to every part of the body, enough to make the 5800-mile round trip between New York and San Francisco close to ten times. [Read more…]
QHP Capital Acquires Applied StemCell
Strategic Financial Sponsor to Support Continued Growth and Market Expansion
October 9, 2023, Raleigh, NC, and Milpitas, CA — QHP Capital (“QHP”), today announced its acquisition of Applied StemCell, Inc. (“ASC” or the “Company”), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 69
- Next Page »